---
title: "博安生物自主開發藥物度拉糖肽注射液獲批上市"
description: "博安生物自主開發的博優平®（度拉糖肽注射液）已獲得國家藥品監督管理局的上市批准，主要用於成人 2 型糖尿病患者的血糖控制。該藥物是一種長效 GLP-1 受體激動劑，商業化由博安生物與上藥控股合作進行。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/252337903.md"
published_at: "2025-08-09T13:58:45.000Z"
---

# 博安生物自主開發藥物度拉糖肽注射液獲批上市

> 博安生物自主開發的博優平®（度拉糖肽注射液）已獲得國家藥品監督管理局的上市批准，主要用於成人 2 型糖尿病患者的血糖控制。該藥物是一種長效 GLP-1 受體激動劑，商業化由博安生物與上藥控股合作進行。

博安生物港交所公告，公司自主開發的博優平®（度拉糖肽注射液）已獲得國家藥品監督管理局的上市批准，用於成人 2 型糖尿病患者的血糖控制。博優平®是一種長效 GLP-1（胰高血糖素樣肽-1）受體激動劑，其在中國大陸的商業化由公司與上藥控股合作開展。

### Related Stocks

- [06955.HK - 博安生物](https://longbridge.com/zh-HK/quote/06955.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| UBTECH Robotics Calls March EGM to Approve 43% Stake in Zhejiang Fenglong Electric | UBTECH Robotics Corp Ltd has scheduled an extraordinary general meeting on March 10, 2026, in Shenzhen to seek sharehold | [Link](https://longbridge.com/zh-HK/news/276118745.md) |
| Novautek Technologies expects loss of HK$30.5 million for HY | Novautek Technologies expects loss of HK$30.5 million for HY | [Link](https://longbridge.com/zh-HK/news/275923659.md) |
| Madagascan cobalt producer Ambatovy's operations hit by cyclone, traders say | Madagascan cobalt producer Ambatovy's operations hit by cyclone, traders say | [Link](https://longbridge.com/zh-HK/news/275920460.md) |
| Wynn Macau's Adjusted Pre-Tax Earnings Fall in Q4 2025 | Wynn Macau's Adjusted Pre-Tax Earnings Fall in Q4 2025 | [Link](https://longbridge.com/zh-HK/news/275832737.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。